On September 1, HANSOH PHARMA fell 3.28% in regular trading to HK$34.2/share, with turnover of HK$143 million. The decline marks a continuation of profit-taking pressure following the company's strong interim results released on August 26, which had triggered a surge of over 16% on August 27.

The company reported first-half revenue of RMB 8.304 billion, up 11.7% year-over-year, with attributable profit rising 35.8% to RMB 4.258 billion, a record half-year high. Innovative drug revenue reached RMB 7.092 billion, accounting for a historic 85.4% of total revenue. Despite the beat, market participants noted that post-earnings euphoria has faded, with some viewing current valuations as having fully priced in optimistic expectations. Concerns over rising sales expenses tied to new product launches and potential margin compression from national reimbursement negotiations have also weighed on sentiment.

The broader pharmaceutical sector added further drag, with Luye Pharma down 2.58%, CSPC Pharma down 0.43%, and China Grand Pharmaceutical down 1.86%, reflecting subdued industry-wide sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)